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Abstract
Background:  Bone tumours are comparatively rare tumours and delays in diagnosis and
treatment are common. The purpose of this study was to analyse sociodemographic risk factors
for bone tumour patients in order to identify those at risk of prolonged patients delay (time span
from first symptoms to consultation), professional delay (from consultation to treatment) or
symptom interval (from first symptoms to treatment). Understanding these relationships might
enable us to shorten time to diagnosis and therapy.
Methods: We carried out a retrospective analysis of 265 patients with bone tumours documenting
sociodemographic factors, patient delay, professional delay and symptom interval. A multivariate
explorative Cox model was performed for each delay.
Results: Female gender was associated with a prolonged patient delay. Age under 30 years and
rural living predisposes to a prolonged professional delay and symptom interval.
Conclusion: Early diagnosis and prompt treatment are required for successful management of
most bone tumour patients. We succeeded in identifying the histology independent risk factors of
age under 30 years and rural habitation for treatment delay in bone tumour patients. Knowing
about the existence of these risk groups age under 30 years and female gender could help the
physician to diagnose bone tumours earlier. The causes for the treatment delays of patients living
in a rural area have to be investigated further. If the delay initiates in the lower education of rural
general physicians, further training about bone tumours might advance early detection. Hence the
outcome of patients with bone tumours could be improved.
Background
Bone tumours are comparatively rare tumours; a report of
the American Cancer Society revealed an estimate of 2500
new bone tumours annually for the whole of the United
States [1]. Furthermore, symptoms of bone neoplasms are
often vague and misleading [2]. Therefore, delays of diag-
nosis and treatment of these tumours are common [2-10].
There has been a remarkable increase in survival rates for
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various bone tumours in recent decades [11-14]. There-
fore, a shortening of diagnostic and treatment delay must
be an objective of successful bone tumour management
[2,11,12,15,16]. Many studies have been undertaken to
investigate treatment or prognosis of bone tumours, but
studies about diagnostic and treatment delays are rare.
The period of time between first symptoms and initial
treatment can be divided into two main categories: patient
delay, which is defined as the time that passes between
first symptoms and first consultation of a physician, and
professional delay, which is mainly caused by the doctor
and defined as the time span between first consultation
and initial treatment. The addition of these two delays,
the time from first symptoms to the first treatment, is
called overall symptom interval [6].
The goal of shortening these delays might be attained by
identifying the "at risk" group of patients through socio-
demographic risk factors. These factors might be attrib-
uted to the patient, the doctor or both and are broadly
known for many other tumour types [17-20].
Delays of diagnosis for bone tumours have been studied
for children [5,6,19] and to some extent for older patients
[2,3]. But in these studies only a specific tumour type was
analysed and therefore the identified risk factors are only
tumour type specific. It remains unclear if some "more
universal" risk factors for diagnostic and treatment delays
of bone tumour patients beneath tumour type specific
ones exist.
However so far to our knowledge no study has been
undertaken aiming at developing such a non tumour type
specific sociodemographic risk profile.
Therefore, the purpose of our study was the analysis of
sociodemographic risk factors in order to identify the
endangered patient for a prolonged diagnostic or treat-
ment delay. Understanding these relationships might ena-
ble us to improve diagnosis and treatment of bone
tumour patients.
Methods
We carried out a retrospective analysis at the senior
author's clinic from 1988 to 1998. Patients with a primary
or secondary bone tumour that meet one of the following
criteria have been included into our study (n = 265): a)
tumours differentiation could not be clarified in the X-ray
examination and a diagnostic surgical biopsy was neces-
sary b) benign tumours that required surgical filling due
to biomechanical reasons to prevent fractures.
To develop a sociodemographic risk profile, the following
data were assembled: date of birth, gender, profession
(scholars, employees, non-employed persons, pension-
ers), place of residence [village/small town (<50000),
metropolis (>50000)], kind of habitation (apartment
sharing, single), nationality (native, foreign).
The histology of the tumour was recorded and grouped
according to the differentiation of the tumour (benign,
semi benign and malignant) and genesis (primary bone
tumour, metastases with known primary tumour, metas-
tases with unknown primary tumour).
For each patient three time-points had been recorded:
date of first symptoms, date of first consultation of a med-
ical doctor, date of first specific treatment. A patient was
considered to be symptomatic from the day that unre-
lieved symptoms, directly attributable to the bone
tumour, were first recorded. As a first specific treatment,
operative and non operative procedures such as chemo-
therapy or conservative therapy by a surgical corset were
defined. The following periods of time were calculated by
use of these three dates [6]: 1. Patient delay: time from
first occurrence of symptoms of the tumour to the first
medical consultation. 2. Professional delay: time from the
first medical consultation to the first specific treatment. 3.
Symptom interval: total period between presenting first
symptoms and the first specific treatment.
Statistics
All time to event data were analysed for significant associ-
ations with explanatory factors on the length of time inter-
vals using nonparametric methods to avoid special
assumptions on the distributions of the underlying data:
Kaplan-Meier estimates of cumulated rates when analys-
ing univariant risks and Cox proportional hazards regres-
sion models to fit multivariate risk patterns using
backward elimination and forward selection algorithms
based on likelihood ratio statistics. Hazard ratios (HR) are
given together with their 95% confidence intervals (95%-
CI) as resulting from the final model step when using
stepwise algorithms or intermediate steps as indicated.
Due to the modelling of the length of the delay intervals,
hazard ratios lower than 1 correspond to prolonged delay
intervals and hazard ratios higher than 1 correspond to
shortened ones. Reflecting the hypotheses generating
character of our analyses, all p-values cited are given as
nominal values, i.e. they are uncorrected for multiple test-
ing situations and consequently may be interpreted
merely in an explorative manner. All computations were
done using SPSS® for Windows® software (version 12).
Results
A summary of the investigated sociodemographic factors
is shown in Table 1. The age of the 265 patients at present-
ing first symptoms was in mean 50 years (range 5 to 87
years).BMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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Histological analyses of the tumours yielded 40 malig-
nant primary bone tumours, 80 benign bone tumours, 20
semi malignant bone tumours and 125 metastases (Table
2). Analysing the patient delay, we calculated a mean
patient delay of 8 weeks (range 0 to 72.1 weeks, Figure 1).
The mean professional delay was 15.7 weeks (range 0.3 to
100.9 weeks, Figure 2), the mean symptom interval 23.5
weeks (range 1.4 to 115.7 weeks, Figure 3). A summary of
the delays attributed to sociodemographic criteria is
shown in Table 3.
Cox Regression Model
To verify the prognostic impact of independent sociode-
mographic factors on patient delay, professional delay,
and symptom interval, we fitted different explorative mul-
tivariate Cox regression models for each delay. The criteria
differentiation of the tumour and genesis were included
into the Cox models, reflecting that for example a known
prior tumour might have influenced the patient or the
physician to accelerate tumour-specific examinations or
diagnostics:
1. A first explorative Cox regression model for patient
delay starting with the covariate set (p-values of Wald's
statistic) profession (p = 0.540), place of residence (p =
0.427), gender (p = 0.123), age at first symptoms (p =
0.418), kind of habitation (p = 0.909), nationality (p =
0.625), differentiation of the tumour (p = 0.423) and gen-
esis (p < 0.0001) yielded the following final result when
using a stepwise elimination algorithm: the first factor
modelling a statistically significant impact on the length
of patient delay was genesis. Information about a prior
tumour was associated with a significantly shorter patient
delay as compared to when this information was missing,
i.e. in case of metastases and unknown primary tumour or
primary bone tumour (HR = 3.122 (95%-CI:
2.350–4.146), p < 0.0001). Beside this, only gender
remained as a statistically independent covariate in the
final model: female gender being associated with a pro-
longed patient delay as compared to male gender (HR =
0.798 (0.625–1.019), p = 0.072). No significant effect was
seen (p-values at step the covariate was eliminated) for
age at first symptoms (p = 0.288), the differentiation of
the tumour (p = 0.456), profession (p = 0.560), place of
residence (p = 0.563), kind of habitation (p = 0.909) and
nationality (p = 0.600). The preliminary step 4 of this Cox
Model is shown in Figure 4.
2. An explorative Cox regression model for professional
delay started with the same set of covariates (p-values of
Wald's statistic): profession (p = 0.280), place of residence
(p = 0.097), gender (p = 0.428), age at first symptoms (p
= 0.110), kind of habitation (p = 0.531), nationality (p =
0.501), differentiation of the tumour (p = 0.289) and gen-
esis (p = 0.003). The backward elimination algorithm
stopped with modelling a significant impact of the
patient's age (p = 0.007) on professional delay: both lev-
els, age between 30 and 60 (HR= 1.379 (95%-CI:
0.957–1.988), p = 0.084) and age over 60 (HR = 1.804
(1.236–2.633), p = 0.002) corresponded to a shortened
professional delay when compared to the level age under
Table 2: Histology. Histology of the 265 tumours is listed below.
Histology Number (n) Percent
Chondro-/Osteosarcoma 40 15.1
Giant cell tumour/aggressive fibromatosis 20 7.5
Osteoidosteoma 13 4.9
Other benign primary bone tumours 67 25.3
Metastases with known primary tumour 75 28.3
Metastases without known primary 
tumour
50 18.9
Total 265 100
Table 1: Sociodemographic factors. Summary of the acquired 
sociodemographic factors of the investigated population. 
Additionally, genesis and differentiation of the tumour are 
listed.
Number (n) Percent
Patients 265 100
Gender
female 143 54.0
male 122 46.0
Age
0–30 51 19.2
30–60 114 43.0
60–90 100 37.7
Profession
employees 88 33.2
scholars 28 10.6
non-employed persons 40 15.1
pensioners 109 41.1
Place of residence
villages/small towns 161 60.8
metropolis 104 39.2
Kind of habitation
apartment sharing 202 76.2
single 63 23.8
Nationality
native 251 94.7
foreign 14 5.3
Differentiation
benign 80 30.2
semi malignant 20 7.5
malignant 165 62.3
Genesis
primary bone tumour 140 52.8
metastases without known 
primary tumour
50 18.9
metastases with known 
primary tumour
75 28.3BMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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30 years. Similarly, the anamnestic status known prior
tumour was significantly associated with a shorter profes-
sional delay when compared to prior tumour unknown
(HR = 1.823 (1.367–2.431), p < 0.0001). The criterion
rural habitation corresponded to a prolongated profes-
sional delay, but marginal missed level of significance (p
= 0.097). Figure 5 resumes the prognostic factors on the
Kaplan Meier chart of professional delay. Figure 2
Kaplan Meier chart of professional delay. A dia-
grammed a mean professional delay of 15.7 weeks (median 
13 weeks; range 0.3 to 100.9 weeks).
Table 3: Summary of the delays for each sociodemographic factor. The detected patient delay, professional delay and symptom 
interval are shown for each sociodemographic factor. Furthermore, the delays for the subgroups genesis and differentiation of the 
tumour are listed.
Patients Patient delay (weeks) Professional delay (weeks) Symptom interval (weeks)
Gender
female 8.7 15.1 23.8
male 7 16.3 23.3
Profession
employees 8.1 17.6 25.7
scholars 11.4 18.2 29.5
non-employed persons 12.7 11.8 24.4
pensioners 6.9 13.2 20.1
Place of residence
villages/small towns 9.1 17.3 26.4
metropolis 6.3 12.9 19.2
Kind of habitation
apartment sharing 8 15.9 23.9
single 7.7 14.7 22.4
Nationality
native 7.9 15.7 23.6
foreign 8.8 14.6 23.4
Differentiation
benign 10.8 20.5 31.3
semi malignant 10.1 19.2 29.3
malignant 6.2 12.9 19.1
Genesis
primary bone tumour 10.5 19 29.5
metastases without known primary tumour 8.6 14.6 23.2
metastases with known primary tumour 2.7 10 12.7
Kaplan Meier chart of patient delay Figure 1
Kaplan Meier chart of patient delay. A mean patient 
delay of 8 weeks (median 6.5 weeks; range 0 to 72.1 weeks). 
The number 0 was given when a patient never had symptoms 
attributed to a tumour before diagnosis.BMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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professional delay which were still included in the prelim-
inary step 4 of our above described final Cox model.
3. A third explorative Cox regression model was fitted for
symptom interval, starting with covariate set (p-values of
Wald's statistics) profession (p = 0.335), place of resi-
dence (p = 0.097), gender (p = 0.989), age at first symp-
toms (p = 0.103), kind of habitation (p = 0.743),
nationality (p = 0.797), differentiation of the tumour (p =
0.165) and genesis (p < 0.0001), and then performing
backward elimination. Similar to the above-mentioned
professional delay, the factor age has been found to have
significant prognostic impact (p = 0.010) on the length of
the symptom interval: again both levels of this covariate,
age between 30 and 60 years (HR = 1.384 (95%-CI:
0.972–1.970), p = 0.072) and age over 60 years (HR =
1.740(1.209–2.505), p = 0.003) significantly corre-
sponded to a shortened symptom interval when com-
pared to the level age under 30 years. Furthermore, the
criterion known prior tumour was significantly associated
with a shortened symptom interval as compared to prior
tumour unknown (HR = 2.566; 95%-CI 1.915–3.438; p <
Kaplan Meier chart of symptom interval. Figure 3
Kaplan Meier chart of symptom interval. The summary 
of the delays, the so-called symptom interval, is shown. The 
mean symptom interval was 23.5 weeks (median 20 weeks; 
range 1.4 to 115.7 weeks).
Cox model of patient delay Figure 4
Cox model of patient delay. This diagram shows step 4 of the Cox model for patient delay. In these Cox diagrams blue bars 
on the left site of the pointed red line indicate a prolonged delay, the blue bars on the right site of the red line indicate a short-
ened delay. As diagrammed above, the criterion metastases of a known primary malignant tumour caused a significantly shorter 
patient delay in comparison to metastases of an unknown primary tumour or a primary bone tumour (p < 0.001). Female gen-
der caused a prolongated patient delay (p = 0.072).BMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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0.0001). Subsequently we fitted a Cox model including all
sociodemographic factors but excluding the differentia-
tion of the tumour and genesis by using stepwise elimina-
tion of covariates. The final model showed again a strong
association of higher age with a shortening of the delay (p
= 0.001) when comparing the two higher age groups older
than 60 years (HR = 1.740 (95%-CI: 1.238–2.445), p =
0.001) and age between 30 and 60 years (HR = 1.992
(1.397–2.841), p = 0.0001) to patients younger than 30
years in our sample. The criterion residence in a metropo-
lis shortened the duration of the symptom interval signif-
icantly as compared to residence in villages/small towns
(HR = 1.388 (1.075–1.791), p = 0.012). No significant
prognostic impact on symptom interval could be detected
(p-values shown for step the covariate was eliminated) for
profession (p = 0.426), gender (p = 0.789), kind of habi-
tation (p = 0.669) and nationality (p = 0.555) (Figure 6).
To clarify whether the negative impact of a younger age on
professional delay and symptom interval could be caused
by genesis or differentiation of the tumour, we investi-
gated the influence of the factor age within each of the fol-
lowing groups: prior tumour known, prior tumour
unknown, malignant tumour, benign tumour. The factor
age had a significant prolonging effect on professional
delay and symptom interval in each group.
Discussion
Our study confirmed that delays in diagnosis of bone
tumours are common. The long duration of the symptom
interval was caused by both, patient and doctor. These
delays are broadly known and identified as a huge obsta-
cle for prompt diagnosis and treatment of bone tumour
patients [2-10].
There are several reasons for the long delay. The most
important reason is that bone tumours are rare and that
symptoms of bone tumours are often vague and mislead-
ing [1,2]. Therefore, patient and physician often assume
Cox model of professional delay Figure 5
Cox model of professional delay. Intermediate step 4 of the final Cox model for professional delay demonstrates that the 
factor age <30 years had a significantly negative impact yielding a prolongation of the professional delay in comparison to elder 
patients (p = 0.007). Residence in a rural area predisposes to a prolonged professional delay (p = 0,097). The criterion known 
primary tumour kept its accelerating nature when compared to unknown tumours (p = 0.002).BMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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more frequent diseases like tendinitis, sciatic pain or oste-
oarthritis to be the cause of these symptoms [10].
Aim of this study was to identify the endangered patient
for a prolonged patient delay, professional delay or symp-
tom interval by means of sociodemographic risk factors.
Therefore we based our statistical exploration on observa-
tions of patients with bone tumours, differing with respect
to the differentiation of the tumour, prognosis, and neces-
sity of treatment. Only bone tumours with the necessity of
a surgical diagnostic or therapeutic intervention have
been included into the study. Patients with a radiological
clear benign tumour without a necessity of biopsy or treat-
ment have not been included into our study. Therefore we
focused only on delays of tumour patients in which early
diagnosis or treatment may be essential.
To deal with the problem of detecting histology inde-
pendent risk factors for a treatment delay in bone tumours
we fitted multivariate Cox models including primarily
sociodemographic factors and adding genesis and differ-
entiation of the tumour in contrast [21].
It has been purpose but at the same time limitation of our
study that the variety of different tumours have not been
classified by individual tumour diagnosis however in cat-
egories of tumour differentiation and genesis. Hence
potential specific characteristics of single tumour types
may not be recognized. Furthermore some predictive and
prognostic factors may cease to be significant if breaking
the cohort down by single tumour types.
In our study we identified certain risk factors leading to a
lagged diagnosis of bone tumours and therefore a treat-
ment delay. The prognostic values of the sociodemo-
graphic factors are discussed below:
Age
Our multivariate analyses showed no statistical influence
of the factor age on the patient delay. But in contrast the
physician needed significantly more time for patients
Cox model of symptom interval Figure 6
Cox model of symptom interval. Step 1 of the Cox model for symptom interval is shown. In this model the factor age <30 
years (p < 0.001) and residence in a rural area (p = 0.012) had a significant impact on prolongation of the symptom interval.BMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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younger than 30 years in comparison to older patients
before initiating the first specific therapy: in our multivar-
iate analysis the factor age under 30 years had a significant
negative impact on professional delay, i.e. youngest
patients showed longer periods until a first specific ther-
apy was realised than older ones.
Consequently, turning the attention on the symptom
interval, age under 30 years was associated with longer
periods from first symptoms to first specific therapy than
more advanced age. Knowing that the age of the patient
did not cause a striking impact on patient delay but on
professional delay, this delay seems to be overwhelmingly
caused by the physician. To ensure that this result had no
statistical effect created by the biology of the tumour or a
known prior tumour in the sense that malignant tumours
occur more frequently in older age and younger patients
might have more benign tumours, we included differenti-
ation and genesis of the tumour into the multivariate Cox
models: surprisingly, differentiation of the tumour had no
significant effect on patients delay, professional delay or
symptom interval. If analysing subgroups of patients with
malignant or benign tumours in view of the factor age, the
criterion age under 30 years maintained the negative
impact independently of the differentiation of the
tumour. In the same way the prolonging effect of age
under 30 years remained independently of tumours gene-
sis: analysing the effect of the criterion age within the sub-
groups prior tumour known or prior tumour unknown
the factor age under 30 years significantly predisposes to a
longer symptom interval. Summing up in our study the
factor age under 30 years significantly predisposes to a
prolonged professional and symptom interval irrespective
of tumours differentiation or genesis.
To our knowledge, there are just four studies which inves-
tigated the effect of age on delay for bone tumours: three
of them included exclusively children or patients younger
than 30 years and found a significant influence of the age
on symptom intervals [6,10,19]. Another study including
only high grade osteosarcoma found no coherence
between symptom interval and age [3]. Our study could
provide evidence about a prolonged professional delay
and symptom interval for young patients with bone
tumours. The fact that younger people have longer profes-
sional delays and symptom intervals is known for numer-
ous other tumour types [18].
The finding that physicians of our population needed
more time to diagnose bone tumours in young people
might originate in the rarity of tumours in younger peo-
ple. Thus it is more likely to go unnoticed by both patients
and their health professionals. The diagnosis tumour is
frequently not being something the physicians initially
consider because the patient is apparently fit, healthy or
too young. This assumption is supported by others report-
ing a high percentage of false diagnosis on patients
younger than 30 years with bone tumours, such as 31% of
diagnosed tendinitis or 12% of diagnosed uncertain pain
at an unseen osteosarcoma [10]. However, ongoing stud-
ies of different populations are necessary to verify the his-
tology independent risk factor age under 30 years for a
treatment delay of bone tumours.
Place of Residence
We detected that the criterion rural habitation caused a
significant prolongation of the overall symptom interval.
Surprisingly, this factor had no significant influence on
patient delay but was associated with an extended profes-
sional delay. A clue for an explanation of the prolonged
professional delay and symptom interval for patients with
bone tumours who live in a rural area may be provided by
the following facts:
The level of urbanization has long been recognized to
affect patient access to health care [22]. It is commonly
known that there is a lower supply of physicians practic-
ing in rural areas relative to the population size [23]. In
view of the rural health system, Koil et al. have shown that
rural practice physicians experience stronger barriers to
referral [22]. Another important point might be that rural
doctors have less access to continuing education courses,
fellow practitioners, and tumour conferences [22,24], all
of which serve to educate physicians about bone cancer
management. As mentioned above, bone tumours are
very rare and therefore a general practitioner will see only
few of them in his whole working life [10].
Differences in specialty mix between clinical practise loca-
tions may also contribute to differences in referral prac-
tice. Rural regions are known to have a greater proportion
of general physicians. In contrast, approximately 90% of
specialist physicians are located in urban and suburban
areas.
Another important fact might be that within our health
care system patients from rural regions contact a general
practitioner as fast as patients from a metropolis do, but
they have a significantly lower rate of contacting special-
ists such as orthopaedic surgeons or cancer specialists
[25]. Other studies concerning bone tumours have shown
that the professional delay and therefore the overall symp-
tom interval was significantly extended when patients
contacted a general practitioner first in comparison to
accident or emergency departments, influenced by a later
x-ray examination [6].
In conclusion, we hypothesize that the detected pro-
longed professional delay and symptom interval of rural
patients with bone tumours might be caused firstly by theBMC Cancer 2008, 8:22 http://www.biomedcentral.com/1471-2407/8/22
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lower density of physicians and notably bone tumour spe-
cialists in rural areas and secondly by the lower further
training of rural physicians in diagnosis of bone tumours.
So far our database did not differentiate between general
physicians and specialists but it is part of our ongoing
studies.
Gender
An extension of patient delay for female gender was
found, and the multivariate analyses indicated a negative
impact for the female gender concerning patient delay.
The gender had neither a statistically relevant effect on
professional delay nor on symptom interval. The fact that
women with a tumour disease have a prolonged patient
delay is ascertained by other workgroups too and was
explained by the hypothesis that women more often cited
competing priorities of work and family over their own
health [18,26-28].
The longer latency of women with bone tumours before
first consultation might be due to the different way in
which men and women recognise abnormalities, attribute
body changes to illness and assess the seriousness of their
condition [29].
Concerning bone tumours and patient delay, analogously
to our study a longer patient delay for women has been
found for osteosarcoma [10]. In contrast to this others
found a shortening of symptom interval for women with
Ewing's sarcoma [19] and no association between gender
and symptom interval for high-grade osteosarcoma [3].
Finally, the question has to be discussed whether a delay
of diagnosis and treatment causes a worse patient survival
or a reduced quality of life. Trying to challenge the corre-
lation between treatment delay and outcome for the
patient, different workgroups stated that a longer treat-
ment delay does not cause a lower survival rate [2,3,6,30].
The lucid explanation of the authors was that a highly
malignant and maybe metastasised tumour caused earlier
complaints and was therefore correlated to a shorter delay
in treatment. But the nature of this statement is exclusively
descriptive: the approach to shorten diagnostic- and treat-
ment delay would enable us to detect bone tumours ear-
lier and therefore with a smaller local size or a more
localized stage. It is commonly known that a larger
tumour is technically more difficult to resect [15,16] and
that an earlier date of an operation might augment the
opportunity for a successful limb salvage resection [2].
Furthermore, the increasing role of new chemotherapy
regiments and bisphosphonate therapy require a diagno-
sis as early as possible for the best possible success
[11,12]. Otherwise some particular tumours may not ben-
efit by shortening diagnosis and treatment due to the fatal
biological characteristics. Further on it remains undis-
puted that the majority of benign bone tumours do not
require a treatment at all.
In summary shortening of diagnostic and treatment delay
of bone tumour patients is an attractive approach aiming
to improve survival and quality of life even if some
patients may not benefit by early treatment.
Conclusion
Early diagnosis and prompt treatment are required for
successful management of most bone tumour patients. In
our population we succeeded in identifying the histology
independent risk factors age under 30 years and rural hab-
itation for a treatment delay in bone tumour patients.
These findings of our study should be verified by ongoing
studies.
Knowing about the existence of the risk groups age under
30 years and female gender could help the physician to
diagnose bone tumours earlier.
The causes for the treatment delay of patients living in a
rural area have to be investigated further. If the delay ini-
tiates in the lower education of rural general physicians,
further training about bone tumours might advance early
detection. Hence the outcome of patients with bone
tumours could be improved.
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